bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
SUMOylation Also sumoylation. A type of post-translational modification in which a SUMO protein is conjugated to a polar residue of another protein (usually a lysine) via a covalent isopeptide bond. This effectively tags the second protein, making it distinguishable to other biomolecules and in many cases allowing it to participate in specific reactions or to interact with specific protein complexes. SUMOlyation is closely related to ubiquitination, relying on the same E1/E2/E3 enzymes to transfer SUMO to specific recognition motifs in the target protein, though detaching SUMO depends on SUMO-specific proteases. It plays important roles in numerous cellular processes, including protein localization, transcriptional regulation, stress-response pathways, and cell cycle checkpoints, among others. SUMOlyation is also used in the laboratory as a molecular label and to help solubilize proteins which are difficult to purify.
In the quarterfinals, he beat Borna Ćorić in four sets to reach his second major semifinal. There, he lost the first two sets to Pablo Carreño Busta, but came back to win the match in five; this was his first-ever match win from two sets down. He thus advanced to his first major final, where he faced Dominic Thiem. He became the runner-up, losing the final in a final-set tiebreaker despite leading by two sets and twice coming within two points of the title in the final set. Zverev was seeded 6th at the French Open. He beat Dennis Novak, Pierre-Hugues Herbert, and Marco Cecchinato, before losing in four sets to Jannik Sinner. In October, he won two consecutive ATP 250 events in Cologne, which took place in the 2020 ATP Tour because of the cancellation of several tournaments due to the COVID-19 pandemic. In the finals, he defeated Félix Auger-Aliassime and Diego Schwartzman, both in straight sets. Zverev then reached the final of the Paris Masters, beating Nadal in straight sets in the semifinals, where he lost to Daniil Medvedev in three sets. In the ATP Finals, Zverev was eliminated in the group stage after a three-set win over Diego Schwartzman, and straight-set losses to Djokovic and the eventual champion Medvedev.
== Pollepel Island chevaux-de-frise (1776–1777) == Another cheval-de-frise was undertaken across the Hudson between Plum Point on the east bank and Pollepel Island north of West Point. The defenses were never fully completed, and its importance was overshadowed by completion of the Great Chain at West Point the following year.
Tohme, researcher recognized for his work on the genetic diversity of food, Manuel Elkin Patarroyo who is known for his groundbreaking work on synthetic vaccines for malaria, Francisco Lopera who discovered the "Paisa Mutation" or a type of early-onset Alzheimer's, Rodolfo Llinás known for his study of the intrinsic neurons properties and the theory of a syndrome that had changed the way of understanding the functioning of the brain, Jairo Quiroga Puello recognized for his studies on the characterization of synthetic substances which can be used to fight fungus, tumors, tuberculosis and even some viruses and Ángela Restrepo who established accurate diagnoses and treatments to combat the effects of a disease caused by Paracoccidioides brasiliensis.
11 February – Azhar Ali, Labour's candidate in the Rochdale by-election, apologises after a recording of him reportedly saying that Israel had "allowed" the deadly attack by Hamas gunmen on 7 October was obtained by The Mail on Sunday. Labour condemns his remarks but continues to offer its support to his candidacy. 12 February – Labour withdraws its support for Rochdale candidate Azhar Ali. Tracey Crouch, MP for Chatham and Aylesford, announces she is standing down from Parliament at the next general election. Prime Minister Rishi Sunak appears on an hour long GB News People's Forum, where a selected audience of undecided voters are invited to ask him questions. The programme is presented by Stephen Dixon. 13 February – Labour withdraws its support for Graham Jones, the former MP for Hyndburn, who was going to contest the seat at the next general election, after it emerges he attended a meeting at which Azhar Ali made comments about Israel. 14 February – Former Labour Party leader Neil Kinnock endorses Vaughan Gething to lead Welsh Labour as the next First Minister of Wales. Conservative MP Tobias Ellwood tells BBC Radio 4's PM programme that politicians cannot be viewed as "fair game" after a large-scale pro-Palestinian protest outside his family home. 15 February – By-elections take place in Wellingborough and Kingswood. Labour's Gen Kitchen takes Wellingborough, the Conservative Peter Bone's former seat, which he had held with a majority of more than 18,000.
Sources: en.wikipedia.org
=== Motion sickness === Meclizine is effective in inhibiting nausea, vomiting, and dizziness caused by motion sickness. The drug is safe for treating nausea in pregnancy and is a first-line therapy for this use. Meclizine may not be strong enough for especially sickening motion stimuli, and second-line defenses should be tried in those cases.
=== Modern reception === Bloodlines is considered a cult classic. Retrospective critiques continue to praise the game's narrative and degree of choice. In 2009, an article in Rock, Paper, Shotgun declared: "The sense of sorrow comes from the realization that there's nothing like [Bloodlines] on the horizon ... why should there be so few games like this? Oh right, because it's so very hard to do ... the lack of games comparable to Bloodlines is one of the great tragedies of our time." Eurogamer called the game inspirational, with an unmatched level of narrative detail. In 2010, The Escapist called Bloodlines a flawed masterpiece which could have been a genuine masterpiece with more time, money, and staff; although great games may inspire awe, it instead created a devoted fan base which continued to develop the game. In 2006, PC Zone listed Bloodlines the seventh-best PC game which people were unlikely to have played, calling it the "best buggy game ever released". In 2007, the game was 80th on Computer & Video Games' list of its top 100 games, and 86th on PC Gamer's 2014 list of the same; it also appeared in PC Gamer's 2015 edition (moving to 63rd), 2017 edition (moving to 42nd), and 2021 edition (moving to 93rd). In 2008, bit-tech listed Jeanette as the second-best non-player video game character. In 2011, Rock, Paper, Shotgun called Bloodlines one of the most important PC games of all time ("it signposts a direction to a future of games that we were denied"), listing it as one of the 122 Best PC Games Ever.
== Premise == The show's plot centers around the lives of half-sisters Mona and Dee Dee Thorne, who slowly become friends when they move into the same San Francisco apt building. Mona is the daughter of Phyllis Thorne, Charles Thorne's first wife, and Dee Dee is Charles' daughter from his second marriage to Deirdre "Big Dee Dee" Thorne. Initially, Mona resents Dee Dee because Dee Dee grew up in a wealthy and privileged household, while Mona and her mother struggled financially. As adults, Mona is more street-smart and cynical, but prone to impulsive decisions while Dee Dee is charming and optimistic, but naïve at times. Throughout the series, the sisters confront their past resentments and learn to lean on each other as they navigate their issues in work, love, and family.
=== Proposed reform in 2025 === Amendments made to the transitional constitution in February 2025, propose to maintain the council as the collective head of state of Sudan, and empower it to appoint a prime minister, cabinet, state governors and justices. The reformed council is to have eleven members, with six nominated by the Sudanese Armed Forces and three from signatories to the peace agreement.
1-Pyrroline-5-carboxylic acid (systematic name 3,4-dihydro-2H-pyrrole-2-carboxylic acid) is a cyclic imino acid. Its conjugate base and anion is 1-pyrroline-5-carboxylate (P5C). In solution, P5C is in spontaneous equilibrium with glutamate-5-semialdehyde (GSA).
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.